Are you Dr. Hartmann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Lynn Hartmann, MD is an oncologist in Rochester, Minnesota. She is currently licensed to practice medicine in Minnesota. She is a Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1986 - 1988
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1983 - 1986
Northwestern University The Feinberg School of MedicineClass of 1983
Certifications & Licensure
MN State Medical License 1986 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Octreotide in Treating Patients With Cancer-Related Malignant Ascites Start of enrollment: 2005 Oct 01
Publications & Presentations
PubMed
- 316 citationsImmune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsMarta Santisteban, Jennifer M. Reiman, Michael K. Asiedu, Marshall Behrens, Aziza Nassar
Cancer Research. 2009-04-01 - 83 citationsBevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypesStefan Kommoss, Boris Winterhoff, Ann L. Oberg, Gottfried E. Konecny, Chen Wang
Clinical Cancer Research. 2017-07-15 - 5598 citationsIntegrated genomic analyses of ovarian carcinomaDebra A. Bell, Andrew Berchuck, Michael J. Birrer, Jeremy Chien, Daniel W. Cramer
Nature. 2011-06-30
Press Mentions
Tumor Heterogeneity for Differentiation Between Liver Tumors and Normal Liver Tissue in 18F-FDG PET/CTNovember 4th, 2020
Preventive Surgery for Women at High Risk of Breast, Ovarian CancerFebruary 3rd, 2016
Suspicious Breast Mass May Pose Greater Risk Than Previously ThoughtDecember 31st, 2014- Join now to see all
Grant Support
- Mechanisms Of Immune Suppression In Ovarian CancerNational Cancer Institute2009–2011
- Mayo Clinic Spore In Ovarian CancerNational Cancer Institute2009–2011
- Administration CoreNational Cancer Institute2009–2011
- Risk Prediction For Breast Cancer: A Tissue-Based StrategyNational Cancer Institute2008–2011
- PAUL Calabresi Program In Clinical-Translational Research At Mayo ClinicNational Cancer Institute2006–2011
- Mayo Clinical Oncology Research Training ProgramNational Cancer Institute2004–2005
- Mayo Clinical Oncology Research Training ProgramNational Cancer Institute2001–2003
- Prophylctic Mastectomy In Hereditary Breast CancerNational Cancer Institute1999–2002
Professional Memberships
- Member
